Skip to content
2000
Volume 10, Issue 1
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Hepatocyte growth factor (HGF) and it's receptor, cMET, have become the focus on intense scrutiny since its discovery in the late 1980s [1, 2] as regards it role in cancer. HGF is now known to be a potent morphogen that can regulate tissue and organ regeneration and modulate cell morphology, it is a motogen that can stimulate cell motility and migration, and is a mitogen able to regulate cell growth and death and as an angiogenic factor [3]. HGF is can induce both angiogenesis and lymphangiogenesis [3a; 4]. That HGF and cMET have such a diversity of functions has led to intense interest in the clinical setting due to their potential in their prognostic aspect and therapeutic implications as imaging tools. This issue will focus on recent work that shows strong indications for the value of HGF and cMET in clinical settings.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/187152010790231553
2010-01-01
2025-05-13
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/187152010790231553
Loading

  • Article Type:
    Research Article
Keyword(s): angiogenesis; cancer treatment; cMET; Hepatocyte growth factor; imaging; metastasis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test